Hormonal diseases

146 trials 57 recruiting

Filter these 146 trials by phase, country and sponsor.

Open in Search →

Phase 1, first-in-human trial to evaluate the safety, tolerability, and pharmacokinetics of ascending single oral doses of octreotide/ LipOr… Ended

2024-514225-30-00 Acromegalia 1 2023-07-11
Glucagon enhanced insulin absorption in Diabetes Mellitus type 1 Ended

2022-502455-57-01 Diabetes mellitus type 1 4 2023-06-20
A Study of Tirzepatide (LY3298176) in Adult Participants With Type 2 Diabetes Switching From Dulaglutide (SURPASS-SWITCH) Ended

2022-500101-41-00 Type 2 Diabetes 6 2023-06-07
A single and multiple ascending dose study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of AZP-3813, a gr… Ended

2023-503734-47-00 Acromegaly 1 2023-05-26
NIHR127468 - The GHD Reversal Trial Ended

2022-502008-62-00 Growth Hormone Deficiency (GHD) 5 2023-05-17
Investigating cardiometabolic risk factors and changes in chronobiology patterns in patients with autonomous adrenal cortisol secretion Ended

2024-512100-19-00 Mild autonomous cortisol secretion in patients with adr 6 2023-05-15
Bioequivalence of Testosterone Transdermal Gel in Healthy Female Subjects Ended

2022-501514-56-00 Male hypogonadism 2 2023-05-02
A 12-month, randomized, single-blind, placebo-controlled exposure-response study of TCD601 (siplizumab) in new onset type 1 diabetes patient… Ended

2023-506837-31-00 New onset type I diabetes 4 2023-01-27
MORPHINE PHARMACOKINETICS AND –DYNAMICS IN HEALTHY VOLUNTEERS AND PATIENTS WITH OBESITY AND OBSTRUCTIVE SLEEP APNOEA. AN INVESTIGATOR INITI… Ended

2022-500779-29-00 Obesity and Obstructive Sleep apnoea 4 2022-12-01
Evaluation of the effect of phenofibrate on the functions of beta cells in children with new diagnosis of type 1 diabetes Ended

2024-517483-34-00 Evaluation of the effect of phenofibrate on the functio 4 2022-09-21
Dual action weight loss in IIH - IIHDUAL Ended

2024-517120-19-02 Idiopathic Intracranial Hypertension 6 2022-09-02
A study to learn how the study drug elinzanetant (BAY 3427080) affects the way the drug dabigatran moves into, through and out of the body i… Ended

2022-500201-41-00 Healthy volunteers (Vasomotor Symptoms as a sex hormone 3 2022-08-02
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study where subjects with non-pharmacologically treated acromeg… Ended

2024-511924-15-00 Acromegaly 5 2022-04-29
REPLACE - A multi-centre, randomised, double-blinded, placebo controlled 16-weeks study to compare the effect of hydrocortisone and placebo … Ended

2024-513822-53-00 Tertiary adrenal insufficiency 6 2022-02-01
Study to Evaluate the Safety and Efficacy of Paltusotine in Subjects with Acromegaly Ended

2024-511925-71-00 Acromegaly 5 2021-08-05
A trial to assess the long-term safety of octreotide subcutaneous depot in patients with acromegaly Ended

2024-510667-33-00 Acromegaly 5 2021-06-03
Muscle strength and -mass after bariatric surgery - a possible effect of testosterone replacement therapy? Randomized, placebo-controlled an… Ended

2024-517015-73-00 Adipositas and male hypogonadism 6 2020-12-15
A study of osilodrostat in children and adolescents with Cushing's disease Ended

2024-516825-30-00 Cushing's disease 4 2020-09-21
An open label, long-term extension study to evaluate the safety and efficacy of CRN00808 in subjects with acromegaly (ACROBAT ADVANCE) Ended

2024-511921-75-00 Acromegaly 4 2020-02-19
PaTH Forward: A Phase 2, Multicenter, Randomized, Double-Blind, Placebo Controlled, Parallel Group Trial with an Open-Label Extension, Inves… Ended

2024-512967-29-00 Hypoparathyroidism (HP) in Adults 4 2019-09-03
A research study in children with low level of hormone to grow. Treatment is somapacitan once a week compared to Norditropin® once a day Ended

2023-506829-11-00 Growth Hormone Deficiency in children 5 2019-05-29
MIBI-THYR : Value of the combination ultrasonography with Ti-RADS score / dual tracer scintigraphy MIBI-Tc99m/Iodine-123 in the detection of… Ended

2024-516416-22-00 malignancy of thyroid nodules 10 2019-01-17
Pharmacodynamics and safety of human recombinant luteinising hormone in hypogonadotropic hypogonadal men Ended

2024-518159-52-02 Hypogonadotropic hypogonadism 10
"SPI-62 as a Treatment for Hypercortisolism Related to a Benign Adrenal Tumor " Ended

2024-516785-12-00 Hypercortisolism related to benign adrenal tumour 4